Characterization Of Glipizide-Loaded Polymethacrylate Microspheres Prepared By An Emulsion Solvent Evaporation Method
Abstract
Purpose: The purpose of the present investigation was to formulate and evaluate microencapsulated glipizide produced by the emulsion – solvent evaporation method, Method: Microspheres were prepared using polymethacrylate polymers (Eudragit® RS 100 and RL 100) by solvent evaporation method and characterized for their micromeritic properties and drug loading, as well as by Fourier transform infrared spectroscopy (FTIR) and scanning electron microscopy. In vitro release studies were performed in phosphate buffer (pH 7.4). Result: The resulting microspheres obtained by solvent evaporation method were white and free flowing in nature. The mean particle size of microspheres ranged from 420 - 660 μm and the encapsulation efficiencies ranged from 40.27 - 86.67 %. The encapsulation efficiency was also found to be dependant on nature of polymer used in the formulation. The infrared spectra confirmed the stable character of glipizide in the drug-loaded microspheres. Scanning electron microscopy revealed that the microspheres were spherical in nature. From the in vitro drug dissolution studies it was found that the sustaining effect of microspheres depended on the polymer concentration, amount of dispersant used and the type of polymer used in the formulation. The mechanism of drug release from the microspheres was found to be non-Fickian type. Conclusion: Eudragit® microspheres containing glipizide could be prepared successfully by using an emulsion solvent evaporation technique using polymethacrylate polymers, which will not only sustain the release of drug but also manage the complicacy of the diabetes in a better manner.
Keywords: glipizide, Eudragit®, microspheres, controlled release, polymethacrylate.
Tropical Journal of Pharmaceutical Research Vol. 7 (1) 2008: pp. 879-885
Submission of a manuscript to this journal is a representation that the manuscript has not been published previously and is not under consideration for publication elsewhere.
All authors named in each manuscript would be required to sign a form (to be supplied by the Editor) so that they may retain their copyright in the article but to assign to us (the Publishers) and its licensees in perpetuity, in all forms, formats and media (whether known or created in the future) to (i) publish, reproduce, distribute, display and store the contribution, (ii) translate the contribution into other languages, create adaptations, reprints, include within collections and create summaries, extracts and/or abstracts of the contribution, (iii) create any other derivative works(s) based on the contribution, (iv) to exploit all subsidiary rights in the contribution, (v) the inclusion of electronic links from the contribution to third party material where-ever it may be located, and (vi) license any thrid party to do any or all of the above.
